Seroprevalence of SARS-CoV-2 Antibody Before and After Both Vaccination and Natural Infection in China

IF 3.1 4区 医学 Q3 IMMUNOLOGY
Yang Guang, Liu Lina, Liu Hui
{"title":"Seroprevalence of SARS-CoV-2 Antibody Before and After Both Vaccination and Natural Infection in China","authors":"Yang Guang,&nbsp;Liu Lina,&nbsp;Liu Hui","doi":"10.1002/iid3.70184","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>This study aims to analyze the effects of temporal SARS-CoV-2 antibodies in China before and after both vaccination and natural infection, thereby providing an empirical basis for evaluating the effectiveness of various prevention methods, including vaccination.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>IgG antibodies against SARS-CoV-2 were determined using chemiluminescence immunoassays, and antibody data was collected from published articles starting in early 2020 and from patients scheduled for surgery at the Hospital of Dalian Medical University between January 2022 and January 2024.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A SARS-CoV-2 infection epidemic in Wuhan in January 2020 led to a 3.2% seropositivity rate of SARS-CoV-2 antibodies (total antibodies). While the seropositivity rate for SARS-CoV-2 antibodies in mainland China reached 37.2% following the implementation of China's zero-COVID policy and the immunization rate was above 90% in January 2022. By the end of 2022, the Chinese government eased strict control measures, resulting in a SARS-CoV-2 antibody (IgG) positivity rate of 86.7% in January 2023. In January 2024, the positivity rate for SARS-CoV-2 antibodies in post-pandemic was recorded at 94.0%. Antibody levels in the early part of 2023 were considerably higher than those measured in January 2022 (68.66 vs. 10.21, <i>p</i> &lt; 0.05); that in early 2024 were not substantially higher than those in January 2023 (49.29 vs. 68.66, <i>p</i> &gt; 0.05).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The results of this study indicated that the immune barrier established by inactivated vaccines could be disrupted by the natural infection with SARS-CoV-2, resulting in a higher level of antibody production than vaccination. This effect can last for more than a year.</p>\n </section>\n </div>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"13 3","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.70184","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunity, Inflammation and Disease","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iid3.70184","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

This study aims to analyze the effects of temporal SARS-CoV-2 antibodies in China before and after both vaccination and natural infection, thereby providing an empirical basis for evaluating the effectiveness of various prevention methods, including vaccination.

Methods

IgG antibodies against SARS-CoV-2 were determined using chemiluminescence immunoassays, and antibody data was collected from published articles starting in early 2020 and from patients scheduled for surgery at the Hospital of Dalian Medical University between January 2022 and January 2024.

Results

A SARS-CoV-2 infection epidemic in Wuhan in January 2020 led to a 3.2% seropositivity rate of SARS-CoV-2 antibodies (total antibodies). While the seropositivity rate for SARS-CoV-2 antibodies in mainland China reached 37.2% following the implementation of China's zero-COVID policy and the immunization rate was above 90% in January 2022. By the end of 2022, the Chinese government eased strict control measures, resulting in a SARS-CoV-2 antibody (IgG) positivity rate of 86.7% in January 2023. In January 2024, the positivity rate for SARS-CoV-2 antibodies in post-pandemic was recorded at 94.0%. Antibody levels in the early part of 2023 were considerably higher than those measured in January 2022 (68.66 vs. 10.21, p < 0.05); that in early 2024 were not substantially higher than those in January 2023 (49.29 vs. 68.66, p > 0.05).

Conclusions

The results of this study indicated that the immune barrier established by inactivated vaccines could be disrupted by the natural infection with SARS-CoV-2, resulting in a higher level of antibody production than vaccination. This effect can last for more than a year.

Abstract Image

目的 本研究旨在分析中国接种疫苗和自然感染前后时间性 SARS-CoV-2 抗体的影响,从而为评估包括接种疫苗在内的各种预防方法的有效性提供经验依据。 方法 采用化学发光免疫测定法测定 SARS-CoV-2 IgG 抗体,并从 2020 年初发表的文章和 2022 年 1 月至 2024 年 1 月在大连医科大学附属医院接受手术的患者中收集抗体数据。 结果 2020 年 1 月在武汉发生的 SARS-CoV-2 感染疫情导致 SARS-CoV-2 抗体血清阳性率(总抗体)达到 3.2%。而在中国实施零COVID政策后,中国大陆的SARS-CoV-2抗体血清阳性率达到37.2%,2022年1月免疫接种率超过90%。2022 年底,中国政府放松了严格的控制措施,2023 年 1 月,SARS-CoV-2 抗体(IgG)阳性率达到 86.7%。2024 年 1 月,大流行后的 SARS-CoV-2 抗体阳性率为 94.0%。2023 年初的抗体水平大大高于 2022 年 1 月的水平(68.66 vs. 10.21,p < 0.05);2024 年初的抗体水平并没有大大高于 2023 年 1 月的水平(49.29 vs. 68.66,p > 0.05)。 结论 本研究结果表明,SARS-CoV-2 自然感染会破坏灭活疫苗建立的免疫屏障,导致产生比接种疫苗更高水平的抗体。这种效应可持续一年以上。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Immunity, Inflammation and Disease
Immunity, Inflammation and Disease Medicine-Immunology and Allergy
CiteScore
3.60
自引率
0.00%
发文量
146
审稿时长
8 weeks
期刊介绍: Immunity, Inflammation and Disease is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research across the broad field of immunology. Immunity, Inflammation and Disease gives rapid consideration to papers in all areas of clinical and basic research. The journal is indexed in Medline and the Science Citation Index Expanded (part of Web of Science), among others. It welcomes original work that enhances the understanding of immunology in areas including: • cellular and molecular immunology • clinical immunology • allergy • immunochemistry • immunogenetics • immune signalling • immune development • imaging • mathematical modelling • autoimmunity • transplantation immunology • cancer immunology
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信